Using gray-market versions of Lilly’s triple-G leads to relatively poor weight loss, study finds
Eli Lilly’s triple agonist retatrutide appears to be the most effective obesity drug to have reached late-stage trials, with weight loss of up to 25% in Phase 3. This has led growing ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.